Lilly Diabetes Drug Could Breathe New Life into Pipeline

Mar 05, 2014


A late stage study has proved Eli Lilly's experimental, once-weekly medicine for type 2 diabetes is as effective in lowering blood sugar as market-leading Victoza from Novo Nordisk.

The Lilly drug, dulaglutide, a GLP-1 agonist, achieved the primary goal of the 599-patient study by demonstrating non-inferiority to the highest approved dose of the daily drug Victoza after 26 weeks, according to initial results released by the company. The projected blockbuster is the first GLP-1 agonist diabetes medication to measure up to Victoza.

Lilly hopes for U.S. and European approval this year.

Read the Reuters press release

Join the discussion

We welcome your thoughtful comments. Please comply with our Community rules.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments